Sapacitabine - Cyclacel Pharmaceuticals

Drug Profile

Sapacitabine - Cyclacel Pharmaceuticals

Alternative Names: CS-682; CYC-682

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company; Hokkaido University; Kanazawa University
  • Developer Cyclacel Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Arabinonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer
  • Phase I/II Solid tumours
  • No development reported Ovarian cancer
  • Discontinued Cutaneous T cell lymphoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ovarian-cancer in United Kingdom (PO)
  • 28 Mar 2017 Cyclacel Pharmaceuticals completes the phase III SEAMLESS trial in Acute myeloid leukaemia (First-line therapy, In the elderly, Newly diagnosed) in Austria, Belgium, France, Germany, hungary, Ireland, Italy, Poland, Spain, Sweden, United Kingdom and USA
  • 23 Feb 2017 Interim efficacy and adverse events data from the phase III SEAMLESS trial in Acute myeloid leukaemia (In the elderly) where the priamry endpoint was not met was released by Cyclacel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top